VERICEL CORPORATION Accounts Payable
VERICEL CORPORATION (VCEL) had Accounts Payable of $20.61 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-07-30
- 2026-06-30: Accounts Payable, Current $20.61M.
- 2026-03-31: Accounts Payable, Current $19.01M.
- 2025-12-31: Accounts Payable, Current $15.83M.
- 2025-09-30: Accounts Payable, Current $15.34M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $20.61M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $19.01M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $15.83M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $15.34M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $12.86M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $16.75M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $23.85M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $20.88M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $25.22M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $19.43M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $22.35M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $15.05M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $14.40M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $11.13M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $16.93M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $8.11M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $9.68M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $7.75M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $9.02M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $5.58M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $8.13M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $8.83M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $6.75M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $6.47M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $4.54M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $6.40M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $6.34M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $5.28M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $5.25M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $6.20M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $7.11M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $4.58M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $5.01M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $5.77M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $5.55M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $5.97M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $6.27M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $6.33M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $6.54M 10-K · filed 2018-03-05 | |
| 2016-09-30 | $5.47M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $5.30M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $6.29M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $7.59M 10-K · filed 2017-03-13 | |
| 2015-09-30 | $5.00M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $6.12M 10-Q · filed 2015-08-12 | |
| 2015-03-31 | $6.73M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $5.82M 10-K · filed 2016-03-14 | |
| 2014-09-30 | $2.50M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $2.91M 10-Q · filed 2014-08-14 | |
| 2013-12-31 | $2.68M 10-K · filed 2015-03-25 | $2.35M 10-K · filed 2014-03-13 |
| 2012-12-31 | $2.84M 10-K · filed 2014-03-13 | |
| 2011-12-31 | $2.24M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |